Beleave Inc. (CNSX:BE) at the request of the Investment Industry Regulatory Organization of Canada wishes to confirm that the Company’s management is unaware of any material change in the Company’s operations that would account for the recent increase in market activity.
Consistent with the Company’s press release dated September 26, 2016, the Company continues work with Health Canada towards the scheduling of a pre-licensing inspection of its proposed facility.
About Beleave Inc.
Beleave, Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM“) has applied for a license to cultivate and sell medical marihuana pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and has been issued an affirmation letter from Health Canada prior to a request for a pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.
This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the ACMPR licensing process and meeting the requirements of the ACMPR. No assurances are given as to the anticipated timing of delivering the confirmations to Health Canada described in this press release nor the anticipated timing of any pre-licensing inspection. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Connect with Beleave Inc. (CNSX:BE) to receive an Investor Presentation.
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/
Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) announced today that it has been issued a Cease Trade Order (“ CTO ”) by the Ontario Securities Commission (the “ OSC ”) as it no longer expects to file the following periodic disclosure documents (collectively, the “ Documents ”) by June 11, 2021, as previously disclosed:
- audited annual financial statements for the year ended December 31, 2020;
- management’s discussion and analysis relating to the audited annual financial statements for the year ended December 31, 2020;
- annual information form for the year ended December 31, 2020;
- interim financial statements for the period ended March 31, 2021;
- management’s discussion and analysis relating to the interim financial statements for the period ended March 31, 2021; and
- certification of the foregoing filings as required by National Instrument 52-109 – Certification of Disclosure in Issuers’ Annual and Interim Filings .
The Company continues to operate normally and is working diligently with its auditors, MNP LLP, to be in a position to file its Documents on or before June 30, 2021.
Among other things, the CTO revokes the management cease trade order issued by the OSC on April 9, 2021 in respect to certain insiders of the Company, which prohibited those persons from trading in the Company’s securities until such time as the Documents are filed.
Despite the CTO, a beneficial security holder of the Company who is not, and was not at the date of the CTO, an insider or control person of the Company, may sell securities of the Issuer acquired before the date of the CTO if the sale is made through an investment dealer registered in a jurisdiction of Canada on a “foreign organized regulated market”, as defined in section 1.1 of the Universal Market Integrity Rules of the Investment Industry Regulatory Organization of Canada . Holders of Avicanna securities are urged to consult with their own investment advisors or legal counsel about the implications of the CTO.
A copy of the CTO has been posted on the website of the Canadian Securities Administrators at cto-iov.csa-acvm.ca.
About Avicanna Inc.
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
SOURCE Avicanna Inc.
The Company posts updates through videos from the official Company YouTube channel https://www.youtube.com/channel/UC5yBclNIsNf7VrE34iwt8OA .
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the timing for the filing of the Documents. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 and final short form prospectus dated November 27, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com . The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
News Provided by GlobeNewswire via QuoteMedia
Adds two accomplished female directors to the Board
Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the results of its Annual and Special Meeting of Shareholders held on June 10, 2021 (the “Meeting”). Each of the eight individuals nominated for election as a director of Trulieve at the Meeting were elected, including new nominees, Giannella Alvarez and Jane Morreau .
Ms. Alvarez has experience in strategic planning, branding, innovation, consumer insights, technology, and scaling and leading multi-billion dollar businesses. She was the Chief Executive Officer of Beanitos, Inc., a privately held snack food company from January 2018 until December 2019 . Prior to that she was the Chief Executive Officer of Harmless Harvest, Inc., a privately held organic food and beverage company from 2015 until January 2018 . Her experience includes senior global leadership roles at The Coca-Cola Company, The Procter and Gamble Co. and Kimberly Clark .
Ms. Morreau is a seasoned global finance executive with a broad skillset and expertise that also includes supply chain management, manufacturing operations, information technology, retail operations, mergers and acquisitions and corporate strategy. Ms. Morreau is currently employed as the Executive Vice President and Chief Financial Officer of Brown-Forman Corporation, a position she has held since 2014.
“Diversity is an important value for Trulieve. With the appointments of Ms. Alvarez and Ms. Morreau, Trulieve’s Board of Directors is now comprised of 50% women,” said Trulieve CEO Kim Rivers . “We welcome our newest independent board members. Their combined experience in corporate finance and branding will be highly beneficial as we continue building out our U.S. hub strategy.
Rivers continued, “Two long-serving board members did not stand for re-election. As founders of Trulieve, Mr. George Hackney and Mr. Michael O’Donnell have sat on our board since Trulieve’s inception and have provided invaluable contributions to the Trulieve Board during their tenure. I wish them well during their retirement and thank them for their service as Board members.”
The Company put forward the following resolutions to be voted on by shareholders at the meeting, all of which were approved: (i) to set the number of directors at eight; (ii) to re-elect directors for the forthcoming year from the nominees proposed by the Board; (iii) to approve the 2021 Omnibus Incentive Plan; and (iv) to re-appoint MNP LLP, as auditors for the Company and authorization of the Board of Directors to fix the auditors’ remuneration and terms of engagement.
A total of 87,472,070 of the 126,003,739 votes attached to all outstanding shares of the Company on an as-converted basis as at the record date voted at the meeting, representing 69.42% of outstanding shares on an as-converted basis.
Election of Directors:
Each of the directors elected at the Meeting, being Kim Rivers, Giannella Alvarez, Thad Beshears, Peter Healy, Richard May , Thomas Millner , Jane Morreau and Susan Thronson, and will hold office until the next annual general meeting of the Company or until their earlier resignation or removal.
Appointment of Auditors:
MNP LLP were appointed as Auditors of the Corporation for the 2021 fiscal year with the Directors authorized to fix their remuneration.
Trulieve is primarily a vertically integrated “seed-to-sale” company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also has licenses in California, Massachusetts, Connecticut, Pennsylvania and West Virginia. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF .
To learn more about Trulieve, visit www.Trulieve.com .
SOURCE Trulieve Cannabis Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2021/11/c5504.html
News Provided by Canada Newswire via QuoteMedia
The National Football League (NFL) wants to know more about cannabis as a pain reliever, and it’s willing to put up an initial US$1 million for research.
Also this week, a cannabis operator announced plans to buy assets from a languishing producer.
Keep reading to find out more cannabis highlights from the past five days.
NFL pursuing more cannabis information
On Tuesday (June 8), the NFL announced it will dedicate US$1 million to research on using cannabinoids for pain relief. The move was made through the organization’s pain management committee, which is run in collaboration with the NFL Players Association.
“There is a need for better information, better science,” Dr. Allen Sills, the NFL’s chief medical officer, said.
The league confirmed it has engaged players to hear about the use of cannabis for pain relief. Previously the drug was an unsanctioned substance in the eyes of the league.
This week’s news is a stepping stone in the NFL’s decision to adjust its views in regards to cannabis, and comes as drug policy continues to change in the US.
The league said the US$1 million earmarked will be given through up to five grants, which will be sent out near the Thanksgiving holiday.
Operator buys facility from fellow Canadian company
In addition to the initial sum, Cannara will also set up deposit requirements of roughly C$5.7 million. Cannara will pursue a non-brokered private placement to complete the deal.
Zohar Krivorot, president and CEO of Cannara, said the purchase represents a strengthening of the company’s presence in Quebec, its home province.
Cannara CFO Nicholas Sosiak said the purchase will boost the company’s annual output, profitability and overall financial position. He remarked that the deal was fueled by the company’s “confidence in the broader market for competitively priced premium-grade cannabis products and our intention to capture a significant share of it.”
Cannabis company news
- Planet 13 Holdings (CSE:PLTH,OTCQB:PLNHF) collected $11.2 million in sales in May as the company celebrates a steady return to pre-pandemic numbers. “We remain confident about the continuation of this upward trend as Las Vegas reopens to its full potential as well as the upcoming opening of our Orange County SuperStore in July,” Larry Scheffler, co-CEO of Planet 13, said.
- Halo Collective (NEO:HALO,OTCQX:HCANF) confirmed a new partnership with Elegance Brands, a beverage maker, to pursue the development of a cannabis-infused drink line. “Elegance Brands has created a unique and exciting portfolio of THC products, and with this Transaction, we step into one of the fastest-growing segments of the functional beverage market,” Halo CEO Kirin Sidhu said.
- Aurora Cannabis (NASDAQ:ACB,TSX:ACB) launched three new dried flower product SKUs as part of its San Rafael ’71 branded lineup. The new items are Stonefruit Sunset, Lemon Rocket and Driftwood Diesel.
- Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) informed shareholders it has completed its acquisition plan for Solevo Wellness West Virginia, an operator based in West Virginia that holds three dispensary permits, for a total sum of US$650,000.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 89th nationwide.
The dispensary will be located next to the Citrus Park Town Center and helps meet Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The facility joins four other Tampa dispensaries, as well as several more in nearby Clearwater , St. Petersburg , and Largo.
In honor of the Company’s newest dispensary, all patients — from those new to Trulieve to the dedicated Truliever community — will be eligible for a 25% in-store discount at the new dispensary on opening day.
Trulieve Tampa – Citrus Park Grand Opening
8625 Citrus Park Drive, Tampa, FL 33625
Saturday, June 12, 2021, at 9:00 a.m.
In stores and online, patients will find Florida’s largest selection of THC and CBD products in a variety of delivery methods, including edibles, smokable flower, concentrates, tinctures, topical creams, vaporizers, and more. Trulieve also offers home delivery statewide for patients and convenient in-store pickup at each of its 83 dispensaries in Florida .
To assist patients with ordering, Trulieve’s entire catalog of products is available now for online ordering, with in-store pickup or statewide home delivery options available depending on patient preference. Additionally, Trulieve offers complimentary 30-minute virtual consultations with a Trulieve consultant to help navigate questions on products, devices, or review their doctor’s recommendation. Appointments can be made on Trulieve’s website and are open to all patients, whether starting their journey with medical cannabis or those with experience looking for alternative treatment options.
At this time, all visitors are required to wear masks for the duration of their dispensary visit. Only patients and their state-approved caregivers will be allowed inside the waiting room and dispensary until further notice.
For more information, please visit www.Trulieve.com .
Trulieve is primarily a vertically integrated “seed-to-sale” company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also holds licenses to operate in California , Massachusetts , Pennsylvania , Connecticut and West Virginia . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF .
To learn more about Trulieve, visit www.Trulieve.com .
SOURCE Trulieve Cannabis Corp.
View original content: http://www.newswire.ca/en/releases/archive/June2021/11/c4875.html
News Provided by Canada Newswire via QuoteMedia
On June 10, 2021, RCP23, LLC (the “Seller”), a private investment holding company controlled by Benjamin Kovler, CEO and Chairman of Green Thumb Industries Inc. (the “Issuer”) (CSE: GTII) (OTCQX: GTBIF), sold 1,666,667 Subordinate Voting Shares of the Issuer (the “Transferred Shares”) to a third-party qualified institutional buyer at a purchase price of US$30.00 per share in a private transaction.
“This transaction brings Green Thumb a new institutional shareholder who is aligned with management’s long-term vision,” said Manager of RCP23 Benjamin Kovler. “RCP23 has historically sold shares on behalf of our legacy shareholders who invested prior to Green Thumb going public.”
For further information, please contact Investor Relations, Green Thumb Industries Inc., InvestorRelations@GTIgrows.com, Phone: 310-622-8257.
News Provided by GlobeNewswire via QuoteMedia